

2nd December, 2021

To,
The Deputy Manager
Department of Corporate Services,
BSE Ltd, PJ Towers
Dalal Street, Mumbai-01
Scrip Code: 511509

Dear Sir/Madam,

Sub: Outcome of Board Meeting-Reg.

Ref: Regulation 30 & other applicable regulations of SEBI (LODR) Regulations, 2015.

We wish to inform you that the Board of Directors of the Company, at their just concluded meeting *interalia* have transacted the following business:

1. Appointment of Dr. Sankaranarayanan Alangudi (DIN: 02703392) as Whole Time Director of the Company, with effect from 6th January, 2022, subject to the approval of the shareholders.
2. Shifting of Registered Office from 8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate Road no.1, Banjara Hills Hyderabad to Survey # 349/A, Pregnapur Village, Gajwel - 502311, Siddipet District, Telangana, India, subject to the approval of the shareholders.
3. Revision in remuneration of Mr. Viswanath Kompella, advisor.
4. Sale of Non-Agricultural Land of 11 Acres 35 Guntas of the Company situated at SY No.103 & 104 of Lakshmakapally Village, Mulugu Mandal, Siddipet District, Telangana to M/s. Vivobio Discovery Services Private Limited (Wholly Owned Subsidiary) or such other Company as decided by the Board for an amount not less than Rs.13 (Thirteen) Crores.
5. Approved the Postal Ballot notice for seeking consent of the Shareholders for the above items including the appointment of Mr. K. Sri Kalyan (DIN: 03137506) as Whole Time Director of the Company.

Further, in accordance with the circular dated 20th June, 2018, issued by the Stock Exchanges, Dr. Sankaranarayanan Alangudi and Mr. K. Sri Kalyan are not debarred from holding office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/1015 dated 09th September 2015; including the brief profile of the Dr. Sankaranarayanan Alangudi is enclosed in **Annexure-A** to this letter.



The meeting commenced at 06.30 P.M. and concluded at 7.20 P.M.

A copy of this letter is being hosted on the Company's website at www.vivobio.com.

We request you to take the above information on record.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Ltd

A. Karthik
A. Karthik
Company Secretary



Annexure-A

Details of Dr. Sankaranarayanan Alangudi

Sl. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	The Board of Directors in its meeting held on 2 nd December, 2021 approved the appointment of Dr. Sankaranarayanan Alangudi (DIN: 02703392) as Whole Time Director designated as CEO & President for a period of 5 years commencing from 6 th January, 2022. This appointment is subject to approval of shareholders.
2.	Date of appointment/cessation (as applicable) & term of appointment;	For a period of 5 years i.e. from 6 th January, 2022 to 5 th January, 2027.
3.	Brief profile (in case of appointment);	Dr. Sankaranarayanan Alangudi (78 years) is presently serving as a Non Executive, Non-Independent Director on the Board. He is a discovery biologist with more than 40 years of experience in Pharmaceutical R&D. He has a proven track record in establishing drug discovery and development facilities, and implementation of GxP standards/accreditation for various biotech/pharma facilities. He is an accomplished innovator with more than 30 patents in the field of cardiovascular and endocrine specialties. Further his scientific contributions have resulted in over 70 international publications including PNAS. He has also mentored and guided about 20 research theses he has presented his research findings in about 80 scientific conferences. Prior to joining Vivo Bio Tech, he was associated with various premier companies and academic institutions, which include - Torrent Pharma, GVK Biosciences, Postgraduate Medical Institute (PGI), Chandigarh and, BITS, etc.
4.	Qualifications	Ph.D., M. Pharm
5.	Disclosure of relationships between directors (in case of appointment of a director).	None of the Directors/ Key Managerial Personnel of the Company/ their relatives are in any way related or interested, financially or otherwise.

